Superbugs & Superdrugs Conference 2018

SMi Group19 - 20 March 2018, London, UK.
SMi's Superbugs & Superdrugs conference this March will focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.

Programme Hightlights

  • Analyse the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR:
    • Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
    • Steve Holden, Medical Adviser, MSD
  • Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress:
    • Conrad Lichtenstein, CSO, Nemesis bioscience
    • David Brown, Managing Director and Founder, Alchemy Biomedical Consulting
  • Learn about regulatory pathways for the registration of new antimicrobial agents:
    • Mair Powell, Senior clinical assessor, MHRA
  • Evaluate the latest incentives and funding solutions to spur drug discovery:
    • Mark Albrecht, Health Scientist, HHS/ASPR/BARDA
    • Adrian Towse, Office of Health Economics
  • Explore the latest novel alternatives to antibiotics currently in development:
    • Ian Henderson, Professor of Microbial Biology, University Of Birmingham
    • Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    • Cara Cassino, Chief Medical Officer, ContraFect

For further information and to register, please visit:
http://www.superbugssuperdrugs.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...